Redeye: Saniona - A new chapter for tesofensine

Saniona’s partner Medix has initiated a Phase 3 trial for tesofensine in patients with obesity. This study is intended to form the basis for market approval in Mexico. The trial has got off to a flying start and after only a month, 40 percent of the total number of patients have been recruited. 

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Om oss

Saniona är ett forsknings- och utvecklingsbolag som bedriver läkemedelsutveckling av preparat som ska användas till sjukdomar i centrala nervsystemet, autoimmuna sjukdomar och behandling av smärta.